Original Article

RETRACTED ARTICLE: The Effect of COVID-19 Vaccination on Reducing the Risk of Infection, Hospitalization, and Death in Isfahan Province, Iran

Abstract

This article has been retracted on 8th February 2022. See: https://ijph.tums.ac.ir/index.php/ijph/article/view/27797

 

Background: We aimed to evaluate the effect of COVID-19 vaccines in preventing infection, hospitalization, and mortality due to COVID-19 in Isfahan Province, Iran.

Methods: Following a retrospective cohort design, data of all vaccinated individuals since the rollout of vaccination of the general population are analyzed, Mar 2020 to Aug 13, 2021. Moreover, the data of all non-vaccinated people were collected by the census method for this period. The two groups were compared concerning hospitalization and mortality using the Chi-square test. Kaplan-Meyer was also used to calculate the median interval between receiving a vaccine and outcome (hospitalization and death).

Results: Overall, 583434 people have received a second dose of a vaccine from Mar 2020 to Aug 2021, which 74% (n=433403) was Sinopharm, 18.2% (n=106027) AstraZeneca, 3.6% (n=21216) Sputnik, and 3.9% (n=22,788) Barekat. In contrast, 2,551,140 people living in the Isfahan Province did not receive a vaccine. The median interval between injection of the first dose and the hospitalization for those who received Sinopharm, AstraZeneca, Sputnik, and Barekat was 22, 61, 19, and 19 days, respectively. For unvaccinated cases, the rates of infection, hospitalization, and mortality (per 1000 population) were 69.7, 12.1, and 1.04, respectively. In contrast, for vaccinated individuals, these rates were 3.9, 1.08, and 0.09, two weeks after the second dose, respectively.

Conclusion: The highest and lowest reduction in relative risk was for those who received AstraZeneca and Sputnik, respectively.

1. Kerr JR, Freeman AL, Marteau TM, van der Linden SJV ( 2021) . Effect of information about COVID-19 vaccine effectiveness and side effects on behavioural intentions: two online experiments. Vaccines (Basel), 9(4):379.
2. Anderson RM, Vegvari C, Truscott J, Collyer BSJTL (2020). Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet, 396(10263):1614-6.
3. Kadkhoda K (2021). Herd Immunity to COVID-19: Alluring and Elusive. Oxford University Press US:471-472.
4. Del Rio C, Malani PN, Omer SB (2021). Confronting the delta variant of SARS-CoV-2. JAMA, 326(11):1001-1002.
5. Fine P, Eames K, Heymann DL (2011). “Herd immunity”: a rough guide. Clin Infect Dis, 52(7):911-916.
6. Teran RA, Walblay KA, Shane EL, et al (2021). Postvaccination SARS‐CoV‐2 infections among skilled nursing facility residents and staff members—Chicago, Illinois, December 2020–March 2021. Am J Transplant, 21(6): 2290-2297.
7. Bergwerk M, Gonen T, Lustig Y, et al (2021). Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med, 385(16):1474-1484.
8. Baltas I, Boshier FA, Williams CA, et al (2021). Post-vaccination COVID-19: A case-control study and genomic analysis of 119 breakthrough infections in partially vaccinated individuals. Clin Infect Dis, doi: 10.1093/cid/ciab714.
9. Gupta N, Kaur H, Yadav P, et al (2021). Clinical characterization and Genomic analysis of COVID-19 breakthrough infections during second wave in different states of India. Viruses, 7;13(9):1782. doi: 10.3390/v13091782.
10. AlQahtani M, Bhattacharyya S, Alawadi A, et al (2021). Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in association with vaccines and the emergence of variants in Bahrain. Res Square, DOI: 10.21203/rs.3.rs-828021/v1.
11. WHO Coronavirus Dashboard 2021 [556]. Available from: https://covid19.who.int/
12. Paul E, Steptoe A, Fancourt D (2021). Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications. Lancet Reg Health Eur, 1:100012.
13. Ministry of Health and Medical Education (2021). National Document of Covid 19 Vaccination in Iran. Ministry of Health and Medical Education.
14. Jara A, Undurraga EA, González C, et al (2021). Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med, 385(10):875-84.
15. Cohen J, Moutinho SJS (2021). Third time’s the charm? Brazil scales back efficacy claims for COVID-19 vaccine from China. Science:1126.
16. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BFJNRI (2021). Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol, 21(10):626-636.
17. Sauré D, O'Ryan M, Torres JP, Zuniga M, Santelices E, Basso LJJTLID (2021). Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Lancet Infect Dis, 9:S1473-3099(21)00479-5.
18. Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al (2021). BNT162b2 vac-cine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbi-ol Infect, 27(11):1652-1657.
Files
IssueVol 51 No 1 (2022) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v51i1.8311
Keywords
Vaccine COVID-19 Hospitalization Mortality Iran
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Taherian Z, Rezaei M, Haddadpour A, Amini Z. RETRACTED ARTICLE: The Effect of COVID-19 Vaccination on Reducing the Risk of Infection, Hospitalization, and Death in Isfahan Province, Iran. Iran J Public Health. 2022;51(1):188-195.